Good for Business, Lithuania, Markets and Companies, Medicine

International Internet Magazine. Baltic States news & analytics Friday, 29.03.2024, 09:06

Sicor Biotech ups profit to EUR 74 mln in 2016

BC, Vilnius, 24.07.2017.Print version
Lithuania's leading biopharmaceutical manufacturer Sicor Biotech, which is controlled by the international generic drugs producer Teva, posted a net profit of 74.014 million euros for 2016, up by 8.8%, from 68 million euros, in 2015, reports LETA/BNS.

Annual revenue rose by 15.2% to 195.216 million euros, the company said in its 2016 annual report filed with the Center of Registers.

 

Sicor Biotech revenue in the US grew by 4.2% to 131.7 million euros, while the revenue in the Baltic states soared 55.8% to 38.2 million euros. Another 4.9 million euros in revenue was received in Turkey and France each. The company's revenue from drugs production and sales was virtually unchanged over the year at 132.6 million euros, while wholesale in products of Teva and other manufacturers were up 74.2% to 62.5 million euros.

 

Dutch-registered Gatio Investments, which is part of Israel's Teva Pharmaceutical Industries Group, owns 100% of shares in Sicor Biotech.






Search site